Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (SPARROW)

• ClinicalTrials.gov Identifier: NCT01446211
• Recruitment Status: Terminated
• First Posted: October 5, 2011
• Last Update Posted: May 29, 2015
• Sponsor: Nordic Pharma SAS
• Information provided by (Responsible Party): Nordic Pharma SAS

Study Description

Brief Summary:

The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive therapy. Further, to evaluate the safety and quality of life of gusperimus treatment compared to standard treatment in patients with relapse of Wegener Granulomatosis receiving glucocorticoids.

Condition or disease	Intervention/treatment	Phase
Wegeners Granulomatosis	Drug: Gusperimus + glucocorticoids; Drug: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids	Phase 3

Detailed Description:

Wegener Granulomatosis without treatment is life-threatening. The standard treatment with corticosteroids and cyclophosphamide is usually effective at controlling active disease. However, disease relapse is frequent and requires increased exposure to these toxic drugs. In other patients initiation or continuation of these standard drugs is contraindicated due to intolerable side effects. No well-established therapy is available for relapsing patients. They may suffer severe organ damage due to progressive disease, or may die. The proposed indication for gusperimus is the treatment of relapsing Wegener Granulomatosis. The aim of therapy with gusperimus is to induce and maintain remission thereby avoiding further cyclophosphamide and reducing corticosteroid exposure.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 4 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Relapsing GRanulomatosis With POlyangiitis Wegener's Granulomatosis)
• Study Start Date: November 2011
• Actual Primary Completion Date: November 2012
• Actual Study Completion Date: January 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Test group - gusperimus; Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.	Drug: Gusperimus + glucocorticoids; Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
Active Comparator: Control group; The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids. The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function).	Drug: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids; Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids . Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function).

Outcome Measures

Primary Outcome Measures :

1. Response rate [ Time Frame: 52 weeks ]

   The primary efficacy variable is the rate of patients showing a response, with the level of disease activity Birmingham Vasculitis Activity Score (BVAS) ≤ 2, within 24 weeks of trial entry, which is maintained without relapse until the end of the trial (Week 52).

   The primary efficacy endpoint includes:

   i) Remission - defined as the complete absence of active clinical disease, i.e. a BVAS score of 0, for at least two months on a stable prednisone dose of ≤ 10 mg/day.

   ii) Low activity Disease State - persistence of up to two minor BVAS items (BVAS ≤ 2).

Secondary Outcome Measures :

1. Time to response [ Time Frame: From the date of study entry until the first occasion that BVAS is ≤ 2, assessed up to 52 weeks ]
   Time to response (response is defined as the time from study entry to the first occasion that BVAS is ≤ 2, and there has been adherence to the steroid reduction protocol)
2. Response duration [ Time Frame: From the date of response with BVAS≤2 until relapse, assessed up to 48 weeks ]
   Response duration defined as time from response with BVAS≤2 to relapse (relapse is defined as the return or first occurrence of one major and/or three minor BVAS items)
3. Frequency of severe relapses [ Time Frame: Up to 52 weeks ]
   Frequency of severe relapses (defined as at least one major BVAS item)
4. Vasculitis Damage Index (VDI) score change [ Time Frame: 12 months ]
   VDI score change from baseline to month 12
5. Glomerular Filtration Rate (eGFR) change [ Time Frame: 12 months ]
   eGFR change from baseline to month 12 in all patients and in a subgroup defined as having a baseline eGFR ≤ 60mL/min (i.e. renal impairment at baseline)
6. Frequency of Adverse Events (AEs) and Serious Adverse Event (SAEs) [ Time Frame: Up to 52 weeks ]
   Frequency of AEs and SAEs. (Total number of AEs per group according to AE category) (Percentage of patients in each group with a severe AE)
7. Frequency of severe infection [ Time Frame: Up to 52 weeks ]
   Frequency of severe infection (a severe infection is defined as an infection that requires intravenous antibiotics or hospitalisation).(Percentage of patients in each group with a severe infection)
8. Pharmacokinetic parameters at selected sites [ Time Frame: 1st day of gusperimus cycles 1, 6 or 7, 12 or 13 ]
   Pharmacokinetic parameters Area Under the plasmaconcentration - time Curve (AUC), Maximum concentration reached in plasma (Cmax), Time to maximum concentration reached in plasma (Tmax) and Elimination half life in plasma (T½) calculated from the measured plasma samples collected at regular time intervals after administration of gusperimus on the first day of three treatment cycles
9. Short-Form-36 (SF-36) [ Time Frame: 6 months ]
   Pooled physical and mental SF-36 domains change from baseline to month 6
10. Short-Form-36 (SF-36) [ Time Frame: 12 months ]
    Pooled physical and mental SF-36 domains change from baseline to month 12
11. Total corticosteroid exposure [ Time Frame: Up to 52 weeks ]
    The total corticosteroid exposure
12. Questionnaire EQ-5D [ Time Frame: 12 months ]
    Change in EQ-5D between baseline and month 12
13. Frequency of non-severe relapses [ Time Frame: Up to 52 weeks ]
    Frequency of non-severe relapses (defined as at least 3 minor BVAS items with no major BVAS items).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Documented diagnosis of Wegener's Granulomatosis (WG) according to the American College of Rheumatology classification criteria.
2. Diagnosis of WG at least 6 months before entry and initial induction therapy with a combination of Glucocorticoids and an immunosuppressive (Cyclophosphamide or Methotrexate) or rituximab.
3. Relapse of WG with or without ongoing Glucocorticoids, and/or immunosuppressive therapy with Azathioprine/Mycophenolate Mofetil/Methotrexate or Leflunomide. The minimum disease activity is defined by the presence of one new/worse major or three new/worse minor BVAS (version 3) items.
4. Patients between 18 - 75 years.
5. Medically acceptable and reliable contraception method during the study course. (Women should not become pregnant for at least 6 months after Cyclophosphamide treatment).
6. Written informed consent for study participation given by the patient.
7. Patients able and prepared to self-administer the study medication or having a relative/third person able to do it.
8. Ability to read, understand and record information required by protocol

Exclusion Criteria:

1. Other multi-system autoimmune disorders, including systemic lupus erythematosus and anti-Glomerular Basement Membrane disease.
2. Systemic vasculitis due to a viral infection.
3. Cyclophosphamide therapy intolerance, hypersensitivity or contraindication to Cyclophosphamide (active substance or any of the excipients) in patients with severe relapse of WG.

4. Hypersensitivity or contraindication to

   • Spanidin (active substance or any of the excipients) or
   • both Methotrexate (active substance or any of the excipients) and Azathioprine(active substance or any of the excipients) or
   • methylprednisolone, prednisolone or other corticosteroids (active substance or any of the excipients).
5. Underlying medical conditions, which in the opinion of the Investigator place the patient at an unacceptable risk level for participating in a study.
6. Previous randomisation in this study.
7. Cyclophosphamide , intravenous immunoglobulin, anti-cytokine biologic therapies, plasma exchange or Abatacept in the three months prior to entry to the trial. Rituximab, Alemtuzumab or stem cell transplantation is not permitted in the six months prior to entry to the trial.
8. Previous treatment with gusperimus.
9. Participation in another clinical trial with investigational drugs within the last 3 months before screening or during the present trial period.
10. Pregnant or breast-feeding females.
11. Active bacterial/viral infection (Human Immunodeficiency Virus, Hepatitis B, Hepatitis C, Tuberculosis).
12. Patients with Glomerular Filtration Rate (eGFR) < 15 mL/min/1.73m2.
13. Alanine transaminase (ALT), Aspartate aminotransferase (AST), bilirubin, and Alkaline phosphatase (ALP) levels above 2 x the upper normal limit.
14. Inadequate bone-marrow function: White Blood Cells (WBC) < 4000/mm3, haemoglobin < 8 g/dL, neutrophils < 2500/mm3, platelets < 100 000/mm3.

Contacts and Locations

Locations

Czech Republic

Všeobecná fakultní nemocnice v Praze

Praha, Czech Republic, 128 08

Sponsors and Collaborators

Nordic Pharma SAS

Investigators

• Principal Investigator: David Jayne, MD; Addenbrookes Hospital, Cambridge, United Kingdom

More Information

• Responsible Party: Nordic Pharma SAS
• ClinicalTrials.gov Identifier: NCT01446211
• Other Study ID Numbers: NO005-NK103; 2011-001219-30 ( EudraCT Number )
• First Posted: October 5, 2011
• Last Update Posted: May 29, 2015
• Last Verified: January 2015

Keywords provided by Nordic Pharma SAS:

gusperimus; Wegeners granulomatosis; relapse

Additional relevant MeSH terms:

Granulomatosis with Polyangiitis; Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Systemic Vasculitis; Vasculitis; Vascular Diseases; Cardiovascular Diseases; Skin Diseases, Vascular; Skin Diseases; Autoimmune Diseases; Immune System Diseases; Gusperimus; Cyclophosphamide; Methotrexate; Azathioprine; Glucocorticoids; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Reproductive Control Agents